A Cohort Study on the Relationship between Serum Uric Acid Trajectory and Clinical Treatment Efficacy in Patients with Acute Heart Failure
XU Enwen
LI Xueqi
LI Shiguang
ZHANG Qingbin
ZHANG Ruilei
Abstract：Objective To investigate the relationship between serum uric acid(SUA)trajectory and clinical treatment efficacy in patients with acute heart failure(AHF).Methods A total of 100 patients with AHF admitted to Anhui No.2 Provincial People's Hospital from February 2022 to February 2024 were selected,and all received standardized treatment.SUA data measured at different time points were collected,and SUA development trajectories were identified using latent class growth modeling.Patients were classified into a low SUA trajectory group(56 cases),a medium SUA trajectory group(32 cases),and a high SUA trajectory group(12 cases)based on SUA levels,and were further divided into an effective group(77 cases)and an ineffective group(23 cases)according to clinical treatment outcomes.Multivariable Logistic regression was used to analyze the influence of SUA trajectory on clinical treatment outcomes in AHF patients and to identify independent risk factors affecting clinical treatment outcomes.Results The SUA levels in 100 AHF patients at admission,14 days of treatment,end of treatment,and 3 months after treatment were(620.52±102.20)μmol/L,(415.50±82.55)μmol/L,(285.50±60.25)μmol/L,and(200.40±20.25)μmol/L,respectively,showing an overall decreasing trend(F=627.844,P<0.05).There were significant differences among the low,medium,and high SUA trajectory groups in cardiac function classification(class Ⅲ-Ⅳ),serum creatinine levels,and N-terminal pro-B-type natriuretic peptide levels(P<0.05).The inefficiency rates after treatment differed significantly among the low,medium,and high SUA trajectory groups(10.71%vs 31.25%vs 58.33%;Z=8.313,P<0.05).Multivariable Logistic regression analysis showed that cardiac function classification(class Ⅲ-Ⅳ),N-terminal pro-B-type natriuretic peptide,cardiac troponin I,non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio,SUA level,and high SUA trajectory were independent risk factors affecting clinical treatment outcomes in AHF patients(OR=1.722,95%CI:1.252-2.229,P<0.01;OR=1.863,95%CI:1.453-2.272,P<0.01;OR=1.893,95%CI:1.396-2.389,P<0.01;OR=1.900,95%CI:1.406-2.395,P<0.01;OR=1.853,95%CI:1.470-2.237,P<0.01;OR=1.835,95%CI:1.465-2.205,P<0.01).Conclusion There is population heterogeneity in SUA levels among AHF patients,and changes in SUA levels are associated with clinical treatment outcomes.
Keywords：acute heart failureserum uric acid trajectoryclinical treatment efficacycohort study
Publication Date：2025-09-20
Online Publishing Date：2025-09-29(First online date of this platform, not the publication date of the document)
Pages：5( 37-41 )